北京大学学报(医学版) ›› 2021, Vol. 53 ›› Issue (3): 536-542. doi: 10.19723/j.issn.1671-167X.2021.03.016

• 论著 • 上一篇    下一篇

全球新型冠状病毒肺炎疫情发展趋势及严重程度

黄冰,王洪源Δ()   

  1. 北京大学公共卫生学院流行病与卫生统计学系, 北京 100191
  • 收稿日期:2021-01-21 出版日期:2021-06-18 发布日期:2021-06-16
  • 通讯作者: 王洪源 E-mail:why_w2003@163.com
  • 基金资助:
    北京大学抗疫专项(PKU2020PKYZX002)

Analysis of the development trend and severity of the COVID-19 panidemic in the global world

HUANG Bing,WANG Hong-yuanΔ()   

  1. Department of Epidemiology and Health Statistics, Peking University School of Public Health, Beijing 100191, China
  • Received:2021-01-21 Online:2021-06-18 Published:2021-06-16
  • Contact: Hong-yuan WANG E-mail:why_w2003@163.com
  • Supported by:
    Anti-epidemic Project of Peking University(PKU2020PKYZX002)

摘要:

目的: 分析近期各国/地区新型冠状病毒肺炎(简称新冠肺炎)疫情发展趋势及严重程度。方法: 收集截止2021年1月16日各国/地区新冠肺炎疫情数据,回顾性描述疫情规模及整体走势;结合近期新增确诊病例变化趋势、1月10日至16日(第54周)新增确诊病例数、发病密度等指标对疫情严重程度进行分类。结果: 截止2021年1月16日,全球累计确诊病例92 510 419例;第54周新增确诊病例4 849 301例,且仍处于增长状态。从大洲层面看,欧洲、北美洲、亚洲累积确诊病例数超过2 100万例;北美洲、南美洲、亚洲单周新增确诊病例数处于增加状态。从国家/地区层面看,美国、印度、巴西等18个国家/地区累计确诊病例数在100万例以上,占全球累积确诊病例数总数的77.04%。美国、巴西、法国、西班牙、哥伦比亚、英国、俄罗斯、德国、南非、意大利和印度11个国家/地区疫情风险较高,其中美国、巴西、法国、西班牙、哥伦比亚5国新增确诊病例仍处于增加状态,疫情风险更大。截止2021年2月,全球已经有11款疫苗上市,但依旧面临着全球疫苗不足和疫苗分配公平性等方面的问题。结论: 截止2021年1月16日,全球新冠肺炎疫情仍在恶化,多国疫情反复,未得到根本的控制。从各大洲层面看,北美洲、南美洲和欧洲疫情最为严重;从国家/地区层面看,美国、巴西、法国、西班牙、哥伦比亚等国家/地区疫情风险较大。

关键词: 新冠肺炎, 全球, 发展趋势, 严重程度

Abstract:

Objective: To analyze the recent severity of COVID-19 in various countries. Methods: Data were ollected on the epidemic situation of COVID-19 in various countries as of January 16, 2021, and the scale and overall trend of the epidemic were retrospectively described; combined with the recent trend of newly confirmed cases, from January 10 to 16 (the 54th week) and the newly confirmed cases indexes, such as the number and incidence density the severity of the epidemic was classified. Feasible suggestions were put forward based on the variation of the virus,actual data of vaccine research and development and possible existence in many countries. Results: Up to January 16, 2021, there were 92 510 419 confirmed cases worldwide; 4 849 301 new confirmed cases were confirmed in the 54th week, and they were still growing. Among all the continents, the cumulative number of confirmed cases in Europe, North America, and Asia has exceeded 21 million, and the number of new confirmed cases in a single week in North America, South America and Asia were all increasing. Among the countries, the cumulative number of confirmed cases in 18 countries including the United States, India, and Brazil was more than 1 million, accounting for 77.04% of the total number of cumulative confirmed cases in the world. Eleven countries including the United States, Brazil, France, Spain, Colombia, The United Kingdom, Russia, Germany, South Africa, Italy, and India are at higher risk of the epidemic; The United States, Brazil, France, Spain, and Colombia were still experiencing new confirmed cases and increasing status, the risk of the epidemic was greater. Novel coronavirus mutates frequently, up to February 2021, there had been 3 931 mutant genotypes in the world. At the same time, a total of 11 vaccines were successfully launched, however we were still facing some troubles, such as the global shortage of vaccines, the public’s willingness to vaccinate needed to be improved, and equity in the distribution of vaccines. Conclusion: The global epidemic situation is still getting worse, with repeated epidemics in all the continents and countries, and has not been fundamentally controlled. At the continent level, North America, South America, and Europe have the most severe epidemics; at the national level, The United States, Brazil, France, Spain, Colombia and other countries have higher epidemic risks. Focusing on the severely affected countries will help bring the global epidemic under control as soon as possible. Under the premise of ensuring the safety and effectiveness of the vaccines, it is a key and feasible direction to improve the yield and vaccination rate of the vaccines, shorten the onset time of the vaccines and prolong the immune persistence.

Key words: COVID-19, Global, Development trend, Severity

中图分类号: 

  • R181.8

表1

病例近期处于增加状态的国家/地区"

Country/region Newly diagnosed
in the 54th week
Incidence density
in the 54th week/%
Country/region Newly diagnosed
in the 54th week
Incidence density
in the 54th week/%
Brazil 1 362 621 1.71 French Polynesia 394 1.40
Colombia 111 754 2.20 Turks and Caicos Islands 106 2.74
Mexico 94 800 0.74 Philippines 4 12 794 0.12
Turkey 65 534 0.78 Ecuador 7 718 0.44
Canada 53 757 1.42 Guatemala 5 496 0.31
Lebanon 33 147 4.86 Libya 4 015 0.58
Bolivia 12 125 1.04 Venezuela 3 093 0.11
Dominican Republic 10 431 0.96 Ivory Coast 1 683 0.06
Paraguay 6 784 0.95 Ghana 1 520 0.05
Honduras 6 406 0.65 Haiti 394 0.03
Latvia 6 284 3.33 Guyana 276 0.35
Uruguay 6 182 1.78 Madagascar 234 0.01
Lesotho 3 794 1.77 Gabon 125 0.06
Mayotte 379 1.39 Martinique 110 0.29
Indonesia 2 74 078 0.27 Benin 109 0.01
Malaysia 19 958 0.62 Liberia 82 0.02
Zimbabwe 6 449 0.43 America 5 1 650 268 4.99
Mozambique 3 787 0.12 France 124 106 1.90
Cuba 3 273 0.29 Spain 122 348 2.62
Malawi 2 569 0.13 Portugal 61 760 6.06
Democratic Republic of Congo 1 889 0.02 Israel 48 617 5.62
Senegal 1 724 0.10 Peru 21 972 0.67
Rwanda 1 515 0.12 United Arab Emirates 21 672 2.19
Chad 388 0.02 Tunisia 20 162 1.71
Togo 375 0.05 Albania 4 257 1.48
Argentina 3 80 709 1.71 Andorra 457 5.91
Chile 27 799 2.20 Japan 6 42 756 0.34
Kuwait 3 491 0.74 Zambia 8 952 0.49
French Guiana 806 0.78 Niger 783 0.03
Suriname 550 1.42 Jamaica 581 0.20
Cape Verde 539 4.86 Maldives 335 0.62

表2

病例近期处于减少状态的国家/地区"

Country / region Newly diagnosed
in the 54th week
Incidence density
in the 54th week/%
Country / region Newly diagnosed
in the 54th week
Incidence density
in the 54th week/%
Russia 1 165 520 1.13 Qatar 1 419 0.49
Germany 128 055 1.53 Saudi Arabia 1 031 0.03
South Africa 119 116 2.01 Kenya 905 0.02
Italy 114 533 1.89 Uganda 789 0.02
Poland 53 223 1.41 Mauritania 679 0.15
Ukraine 44 677 1.02 Syria 671 0.04
Sweden 34 063 3.37 The Republic of Congo 549 0.10
Romania 24 491 1.27 Angola 547 0.02
Switzerland 17 183 1.99 Uzbekistan 374 0.01
Belgium 13 071 1.13 Mali 373 0.02
Belarus 13 003 1.38 Reunion 196 0.22
Austria 12 331 1.37 Sierra Leone 177 0.02
Hungary 10 128 1.05 Guinea 161 0.01
Denmark 8 823 1.52 Bhutan 66 0.09
Slovenia 8 498 4.09 Sudan 0 0.00
Lithuania 8 498 3.12 Aruba 3 413 3.87
Costa Rica 6 835 1.34 United States Virgin Islands 88 0.84
Palestine 5 815 1.14 Pakistan 4 16 828 0.08
Croatia 5 228 1.27 Egypt 6 810 0.07
Puerto Rico 3 887 1.36 Bangladesh 5 795 0.04
Estonia 3 602 2.72 Kazakhstan 5 259 0.28
Moldova 3 594 0.89 Salvador 1 902 0.29
Montenegro 2 835 4.51 Oman 1 194 0.23
Armenia 2 441 0.82 Kyrgyzstan 848 0.13
Namibia 2 315 0.91 Afghanistan 538 0.01
Cyprus 1 935 1.60 Cameroon 488 0.02
Swaziland 1 354 1.17 Mongolia 96 0.03
Malta 1 235 2.80 South Sudan 89 0.01
Gibraltar 581 17.25 United Kingdom 5 358 547 5.28
Barbados 256 0.89 Czech Republic 61 190 5.71
San Marino 139 4.10 Netherlands 43 115 2.52
Monaco 128 3.26 Ireland 30 664 6.21
Jersey 121 1.22 Panama 22 194 5.14
Liechtenstein 62 1.63 Slovakia 17 516 3.21
India 2 129 424 0.09 Serbia 13 698 1.57
Nigeria 9 867 0.05 Norway 3 942 0.73
Morocco 7 404 0.20 Macedonia 2 795 1.34
Iraq 5 567 0.14 Bosnia and Herzegovina 2 411 0.73
Greece 4 366 0.42 Bahrain 1 991 1.17
Sri Lanka 4 289 0.20 Kosovo 1 871 0.94
Bulgaria 3 491 0.50 Luxembourg 882 1.41
Azerbaijan 3 132 0.31 Iran 6 43 781 0.52
Ethiopia 2 754 0.02 Korea 3 822 0.07
Nepal 2 657 0.09 Algeria 1 203 0.03
Finland 1 843 0.33 Burkina Faso 943 0.05
Thailand 1 839 0.03
[1] 中华预防医学会新型冠状病毒肺炎防控专家组. 新型冠状病毒肺炎流行病学特征的最新认识[J]. 中国病毒病杂志, 2020,10(2):86-92.
[2] Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): a literature review[J]. J Infect Public Health, 2020,13(5):667-673.
doi: S1876-0341(20)30432-9 pmid: 32340833
[3] Ngonghala CN, Iboi EA, Gumel AB. Could masks curtail the post-lockdown resurgence of COVID-19 in the US[J/OL]. Math Biosci, 2020,329:108452(2020-08-18)[2021-01-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431430/
[4] WHO. WHO coronavirus disease (COVID-19) dashboard[EB/OL]. (2020-01-16) [2021-01-17]. https://covid19.who.int.
[5] United Nations. World population prospects 2019[EB/OL]. (2019-8-28) [2020-11-29]. https://population.un.org/wpp/Download/Standard/Population/.
[6] Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia[J]. N Engl J Med, 2020,382(13):1199-1207.
doi: 10.1056/NEJMoa2001316
[7] Wang X, Tang SY, Chen Y, et al. When will be the resumption of work in Wuhan and its surrounding areas during COVID-19 epidemic? A data-driven network modeling analysis (in Chinese)[J]. Sci Sin Math, 2020,50(7):969-978.
doi: 10.1360/SSM-2020-0037
[8] 中华人民共和国国务院新闻办公室. 《抗击新冠肺炎疫情的中国行动》白皮书 [EB/OL]. (2020-06-07) [2020-11-28]. http://www.scio.gov.cn/ztk/dtzt/42313/43142/index.htm.
[9] Lai S, Ruktanonchai NW, Zhou L, et al. Effect of non-pharmaceutical interventions to contain COVID-19 in China[J]. Nature, 2020,585(7825):410-413.
doi: 10.1038/s41586-020-2293-x
[10] 国务院. 国务院应对新型冠状病毒感染肺炎疫情联防联控机制关于做好新冠肺炎疫情常态化防控工作的指导意见[J]. 中国公共卫生管理, 2020,36(3):284-441.
[11] United Nations. China shows COVID-19 coronavirus can be ‘stopped in its tracks’[EB/OL]. (2020-03-16) [2020-12-16]. https://news.un.org/en/story/2020/03/1059502.
[12] Yuan J, Li M, Lv G, et al. Monitoring transmissibility and mortality of COVID-19 in Europe[J]. Int J Infect Dis, 2020,95:311-315.
doi: 10.1016/j.ijid.2020.03.050
[13] Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe[J]. Nature, 2020,584(7820):257-261.
doi: 10.1038/s41586-020-2405-7 pmid: 32512579
[14] Glass DH. European and US lockdowns and second waves during the COVID-19 pandemic[J/OL]. Math Biosci, 2020,330:108472(2020-09-24)[2021-01-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832121/.
[15] 中央纪委国家/地区监委网站. 分析:欧洲疫情为何反弹 [EB/OL]. (2020-10-30) [2020-11-24]. http://www.ccdi.gov.cn/yaowen/202010/t20201030_228981.html.
[16] 高雅. 专访美国公共卫生专家黄严忠为何新冠肺炎疫情如此反复[N]. 第一财经日报, 2020-07-02(A8).
[17] 常宇桐, 刘丽娟, 张丽萍, 等. 变异新冠病毒对口岸疫情防控影响的快速风险评估[J/OL]. 中国国境卫生检疫杂志 (2021-03-11)[2021-03-24]. http://kns.cnki.net/kcms/detail/11.3254.R.20210311.1726.002.html.
[18] Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England[J/OL]. Science, 2021[2021-01-10]. https://science.sciencemag.org/content/372/6538/eabg3055.full.
[19] Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data[J/OL]. MedRxiv, 2021 [2021-01-10]. https://www.medrxiv.org/node/223306.external-links.html.
[20] 张超, 陈姝冰, 张洁, 等. 浅析注册用于新冠肺炎治疗的临床试验药物[J]. 药学学报, 2020,55(3):355-365.
[21] Sjödin H, Wilder-Smith A, Osman S, et al. Only strict quarantine measures can curb the coronavirus disease (COVID-19) outbreak in Italy, 2020[J]. Euro Surveill, 2020,25(13):2000280.
[22] World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines[EB/OL]. (2021-02-23)[2021-03-02]. https:/www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
[23] 陈恩富. 疫苗时代新型冠状病毒肺炎疫情防控策略[J]. 预防医学, 2021,33(3):221-225.
[24] Scudellari M. How the pandemic might play out in 2021 and beyond[J]. Nature, 2020,584(7819):22-25.
doi: 10.1038/d41586-020-02278-5 pmid: 32760050
[1] 金音子, 谢铮, 赵春山, 周书铎, 尹慧, 马继炎, 黄旸木, 郭岩, 刘培龙, 郑志杰. 国际关注的突发公共卫生事件下中国参与全球卫生治理的挑战及对策[J]. 北京大学学报(医学版), 2020, 52(5): 799-802.
[2] 杜建,詹启敏. 后疫情时代促进我国医学发展的思考与建议[J]. 北京大学学报(医学版), 2020, 52(3): 405-409.
[3] 冯文,张靓囡,李璟媛,魏田,彭婷婷,张东旭,郭在新,王伟嵩. 基于互联网的新型冠状病毒肺炎健康咨询服务分析[J]. 北京大学学报(医学版), 2020, 52(2): 302-307.
[4] 路晓燕, 李春, 赵金霞, 栗占国. 2011年ACR/EULAR类风湿关节炎缓解标准与其他常用标准的比较[J]. 北京大学学报(医学版), 2013, 45(2): 260-.
[5] 刘思琦, 沈刚, 白丁, 周洪, 厉松, 陈文静, 王大为7, 李巍然, 耿直8, 许天民. 中国正畸专家对错牙合畸形严重程度的主观判断一致性研究[J]. 北京大学学报(医学版), 2012, 44(1): 98-102.
[6] 郭应禄. 泌尿外科发展战略构想[J]. 北京大学学报(医学版), 2010, 42(4): 363-365.
[7] 郭岩*, 刘培龙, 许静*. 全球卫生及其国家策略研究[J]. 北京大学学报(医学版), 2010, 42(3): 247-251.
[8] 陈贵安. 我国生殖医学的进展[J]. 北京大学学报(医学版), 2004, 36(6): 565-565.
[9] 陆道培. 造血干细胞移植的主要进展--截止到2003年2月[J]. 北京大学学报(医学版), 2003, 35(2): 113-114.
[10] 张震康. 口腔医学科学研究的重要进展和方向[J]. 北京大学学报(医学版), 2002, 34(2): 97-98.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 张三. 中文标题测试[J]. 北京大学学报(医学版), 2010, 42(1): 1 -10 .
[2] 赵磊, 王天龙 . 右心室舒张末期容量监测用于肝移植术中容量管理的临床研究[J]. 北京大学学报(医学版), 2009, 41(2): 188 -191 .
[3] 万有, , 韩济生, John E. Pintar. 孤啡肽基因敲除小鼠电针镇痛作用增强[J]. 北京大学学报(医学版), 2009, 41(3): 376 -379 .
[4] 张燕, 韩志慧, 钟延丰, 王盛兰, 李玲玲, 郑丹枫. 骨骼肌活组织检查病理诊断技术的改进及应用[J]. 北京大学学报(医学版), 2009, 41(4): 459 -462 .
[5] 赵奇, 薛世华, 刘志勇, 吴凌云. 同向施压测定自酸蚀与全酸蚀粘接系统粘接强度[J]. 北京大学学报(医学版), 2010, 42(1): 82 -84 .
[6] 林红, 王玉凤, 吴野平. 学校生活技能教育对小学三年级学生行为问题影响的对照研究[J]. 北京大学学报(医学版), 2007, 39(3): 319 -322 .
[7] 丰雷, 程嘉, 王玉凤. 注意缺陷多动障碍儿童的运动协调功能[J]. 北京大学学报(医学版), 2007, 39(3): 333 -336 .
[8] 李岳玲, 钱秋瑾, 王玉凤. 儿童注意缺陷多动障碍成人期预后及其预测因素[J]. 北京大学学报(医学版), 2007, 39(3): 337 -340 .
[9] . 书讯[J]. 北京大学学报(医学版), 2007, 39(3): 225 -328 .
[10] 牟向东, 王广发, 刁小莉, 阙呈立. 肺黏膜相关淋巴组织型边缘区B细胞淋巴瘤一例[J]. 北京大学学报(医学版), 2007, 39(4): 346 -350 .